Trial Outcomes & Findings for Evaluation of the Effectiveness of tDCS in the Management of Perioperative Pain (NCT NCT01861587)

NCT ID: NCT01861587

Last Updated: 2018-08-07

Results Overview

The PCA pump usage was downloaded from the PCA pump after discharge from the hospital.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

27 participants

Primary outcome timeframe

Participants were followed for the duration of hospital stay, an average of 48 hours.

Results posted on

2018-08-07

Participant Flow

Participant milestones

Participant milestones
Measure
Real tDCS:Active Comparator
For Real tDCS, stimulation will be delivered in 20-minute-sessions using 2mA current. The anode will be placed over left BA9 or the motor cortex corresponding with the painful area (if applicable). The cathode will be placed over right BA43 (for GI pain) or right BA9 (located via the international 10-20 EEG system).
Sham tDCS: Sham Comparator
For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
Overall Study
STARTED
14
13
Overall Study
COMPLETED
14
13
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Evaluation of the Effectiveness of tDCS in the Management of Perioperative Pain

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Real tDCS:Active Comparator
n=14 Participants
tDCS: 20 minutes of either real or sham stimulation
Sham tDCS: Sham Comparator
n=13 Participants
tDCS: 20 minutes of either real or sham stimulation
Total
n=27 Participants
Total of all reporting groups
Age, Continuous
59.4 years
STANDARD_DEVIATION 2.1 • n=5 Participants
59.4 years
STANDARD_DEVIATION 2.1 • n=7 Participants
59.4 years
STANDARD_DEVIATION 2.1 • n=5 Participants
Sex: Female, Male
Female
9 Participants
n=5 Participants
8 Participants
n=7 Participants
17 Participants
n=5 Participants
Sex: Female, Male
Male
5 Participants
n=5 Participants
5 Participants
n=7 Participants
10 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
2 Participants
n=5 Participants
2 Participants
n=7 Participants
4 Participants
n=5 Participants
Race (NIH/OMB)
White
12 Participants
n=5 Participants
11 Participants
n=7 Participants
23 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
United States
14 participants
n=5 Participants
13 participants
n=7 Participants
27 participants
n=5 Participants

PRIMARY outcome

Timeframe: Participants were followed for the duration of hospital stay, an average of 48 hours.

The PCA pump usage was downloaded from the PCA pump after discharge from the hospital.

Outcome measures

Outcome measures
Measure
Real tDCS:Active Comparator
n=14 Participants
tDCS: 20 minutes of stimulation at 2mA.
Sham tDCS: Sham Comparator
n=13 Participants
For Sham tDCS, the stimulator was turned off automatically after 45 seconds.
Patient Controlled Analgesia (PCA) Hydromorphone Usage
12.6 milligrams of hydromorphone
Standard Deviation 9.9
16.5 milligrams of hydromorphone
Standard Deviation 12.7

PRIMARY outcome

Timeframe: Baseline and Discharge

To assess each participant's average pain at it's least in the past 24 hours, The Brief Pain Inventory (BPI)-short form will be administered. The BPI rapidly assesses the severity of pain and its impact on functioning and has been widely used in both research and clinical settings. Participants rate their average pain at it's least in the past 24 hours using a 0-10 numerical rating scale, where 0=no pain and 10=extreme pain.

Outcome measures

Outcome measures
Measure
Real tDCS:Active Comparator
n=14 Participants
tDCS: 20 minutes of stimulation at 2mA.
Sham tDCS: Sham Comparator
n=13 Participants
For Sham tDCS, the stimulator was turned off automatically after 45 seconds.
Average Pain at Least
Baseline
4.5 units on a scale
Standard Deviation 2.5
3.5 units on a scale
Standard Deviation 1.6
Average Pain at Least
Discharge
3.2 units on a scale
Standard Deviation 2.2
3.5 units on a scale
Standard Deviation 1.6

PRIMARY outcome

Timeframe: Baseline Only

To assess each participant's average pain at it's worst in the past 24 hours at Baseline, The Brief Pain Inventory (BPI)-short form will be administered. The BPI rapidly assesses the severity of pain and its impact on functioning and has been widely used in both research and clinical settings. Participants rate their average pain at it's worst in the past 24 hours using a 0-10 numerical rating scale, where 0=no pain and 10=extreme pain.

Outcome measures

Outcome measures
Measure
Real tDCS:Active Comparator
n=14 Participants
tDCS: 20 minutes of stimulation at 2mA.
Sham tDCS: Sham Comparator
n=13 Participants
For Sham tDCS, the stimulator was turned off automatically after 45 seconds.
Average Pain at Worst
8.9 units on a scale
Standard Deviation 1.2
8.0 units on a scale
Standard Deviation 2.4

PRIMARY outcome

Timeframe: Baseline Only

To assess each participant's pain on average in the past 24 hours at Baseline, The Brief Pain Inventory (BPI)-short form will be administered. The BPI rapidly assesses the severity of pain and its impact on functioning and has been widely used in both research and clinical settings. Participants rate their pain on average in the past 24 hours using a 0-10 numerical rating scale, where 0=no pain and 10=extreme pain.

Outcome measures

Outcome measures
Measure
Real tDCS:Active Comparator
n=14 Participants
tDCS: 20 minutes of stimulation at 2mA.
Sham tDCS: Sham Comparator
n=13 Participants
For Sham tDCS, the stimulator was turned off automatically after 45 seconds.
Average Pain
7.0 units on a scale
Standard Deviation 1.5
6.3 units on a scale
Standard Deviation 1.4

Adverse Events

Real tDCS:Active Comparator

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Sham tDCS: Sham Comparator

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jeffrey Borckardt, Ph.D

Medical University of South Carolina

Phone: 843-792-3295

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place